Abstract Aim of the work: The present study was undertaken to determine whether mannose binding lectin-2 (MBL2) promotor-221X/Y gene polymorphism had a possible association with systemic lupus erythematosus (SLE) in Mansoura city.
Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that displays a complex spectrum of clinical and immunologic manifestations [1] . It is characterized by a breakdown of self-tolerance and auto-reactive lymphocyte activation against several nuclear and cytoplasmic self-antigens. SLE pathogenesis is multifactorial, and its susceptibility has been associated with genetic, hormonal, immunologic and environmental factors [2, 3] . In a study on Egyptian SLE patients it has been suggested that anti-complement1q (C1q) antibodies in combination with anti-double stranded deoxyribonucleic acid (dsDNA) antibodies may serve as potential reliable and none invasive markers of SLE disease activity and renal involvement to avoid unnecessary renal biopsies [4] .
The ever-increasing researches concerning various genes association with SLE emphasized the contribution of the innate and adaptive immune response genes [5] [6] [7] [8] . Mannose binding lectin (MBL) is a main member of the complement system that is responsible for a vital role in innate immunity. MBL2 gene was detected at the position 10q11.2-21 on chromosome 10. It consists of four exons and three introns. There were two functional single nucleotide polymorphisms (SNPs) in the promotor region of the gene, one located at the position -221 (rs709606 C-G) and the other -550 (rs11003125) and three functional SNPs in exon 1 at codons 52 (C/T, rs5030737), 54 (G/A, rs1800450), and 57 (G/A, rs1800451), known as D, B, and C variant, respectively [9, 10] . SNPs of MBL2 gene are usually associated with differential serum MBL level production and considerable reduction or complete absence of functional MBL protein [11, 12] .
Previous studies suggested that deficiency or low MBL serum levels determined by MBL2 functional SNPs are associated with autoimmune diseases occurrence [13, 14] . The association between MBL2 polymorphisms and SLE development as well as clinical manifestations has been reported. Nevertheless, controversial results have been obtained among various populations [2, 15] . In addition, it has been shown that anti-MBL autoantibodies were present in serum of 52% SLE patients [16] .
In various populations, MBL2 represents candidate gene for SLE susceptibility [17] [18] [19] . It has not been studied among SLE Egyptians while, a recent study detected its association with Egyptian infants with acute respiratory tract infection [20] . The aim of this study was to determine the possible association between MBL2 promotor gene polymorphism and Egyptian SLE patients.
Patients and methods
A case control study was carried out on 106 SLE Egyptian patients and 99 healthy volunteers selected as control in the period from March 2013 to March 2015. Our patients were selected from the Rheumatology and Rehabilitation, Nephrology, Internal Medicine and Clinical Pathology Department at Mansoura University Hospitals. All patients fulfilled the systemic lupus international collaborating clinics classification criteria for SLE [21] . Drug induced lupus and patients with other autoimmune disease were excluded. The study was approved by the Ethics Committee of Mansoura University Hospital. Written informed consent was obtained from all patients.
All patients were subjected to full history taking, complete clinical examination. Disease activity was estimated by SLE Disease Activity Index (SLEDAI) [22] . Disease severity was estimated by systemic lupus international collaborating clinic/American college of rheumatology damage index (SLICC ACR DI) [23] . Renal biopsy was performed on 74 patients who had persistent proteinuria and/or cellular cast. Patients were classified according to International Society of Nephrology/Renal Pathology Society (ISN/RPS) in 2003 classification of lupus nephritis [24] .
2.1. MBL2 gene-221 X/Y promoter region polymorphism genotyping 3 ml of venous blood was collected by clean venipuncture using plastic disposable syringes evacuated in screw capped EDTA tubes and frozen at À20°C until the time of assays. This work was carried out at the molecular biology laboratory (Clinical Immunology Unit), Clinical Pathology Department, Faculty of Medicine, Mansoura University. DNA extraction was done using QIAamp Mini spin column (Qiagen), cat no. 51104. USA and was used for genotyping assays with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The PCR primers were:
Statistical analysis
Categorical data were expressed in numbers and percentages. Data were expressed as mean ± SD or medians and ranges. Independent sample T and Mann-Whitney U tests were used for normally and non-normally distributed data respectively. The association between categorical variables was determined by Chi square or Fisher exact test. Spearman's rho was used to delineate the correlation between numeric indices. Statistical significance was considered at p value <0.05. Data entry and statistical analyses were performed using SPSS (statistical package of social sciences) version 21 (SPSS Inc., Chicago, IL, USA).
Results
One hundred and six SLE patients: 95 females and 11 males (female:male 8.6:1) with a mean age of 34.4 ± 10.2 years and disease duration of 4 ± 3.03 years. Positive family history for SLE was in 7 (6.6%) patients and 18 (16.9%) had positive consanguinity. Healthy control group was 90 female and 9 male (female:male 10:1) with a mean age of 37.5 ± 7.3 years. The clinical and laboratory characteristics of the patients are described in Table 1 . Renal biopsy was performed in 74 (69.8%) of SLE patients and lupus nephritis classes were class II in 3 (2.8%) patients, class III in 45 (42.5%) and class IV in 26 (24.5%) while 32 (30.2%) patients did not undergo renal biopsy.
MBL2-221 X/Y promotor polymorphism
There were 77 (72.6%) SLE patients having the genotype YY while only 29 (27.4%) had the genotype XY. The YY genotype was significantly associated with SLE compared to the control (n = 59; 59.6%) (p = 0.048). However, allele frequency between patients and control groups did not detect any association ( Table 2) .
The relation of MBL2-221X/Y promotor polymorphism with clinical manifestations is presented in Table 3 . Studying the MBL2 promotor gene polymorphism in SLE patients demonstrated a significant association of XY genotype with weight loss (p = 0.027), discoid rash (p = 0.027), alopecia (p = 0.048), neurological symptoms (p = 0.033), vasculitis (p = 0.004), and APL syndrome (p = 0.001), while other variables did not demonstrate any significant associations (p > 0.05). There were no significant correlation between MBL2 promoter genotype with the SLEDAI (r = À0.17, p = 0.08) or SLICC/ACRDI (r = 0.05, p = 0.58).
The relation of the MBL2-221X/Y promotor gene polymorphism with the laboratory investigations in the SLE patients is shown in Table 4 . The MBL2 promotor YY genotype displayed a significant association with low serum complement (p = 0.014) and with the presence of ACL antibodies (p = 0.032). Other measured laboratory data did not display any significant association.
Discussion
Within the studies of genetic susceptibility to SLE, there is growing interest in the clinical significance of MBL variant alleles [26] [27] [28] [29] . Preliminary studies in the UK, Spain, China and Greece suggested a possible association between MBL2 promotor genotype and SLE [30, 31] .
In the current study, a significant association was found between SLE and the YY genotype of MBL2-221 X/Y thus conferring increased disease susceptibility. These results are similar to earlier Chinese [31] and African [32] studies which reported an association between SLE and genotype YY. Contrary to our findings, a meta-analysis involving several European, Asian and African studies concluded that X allele was a risk factor for developing SLE [33] . This disagreement may be explained by different assay techniques used and ethnic differences or by the influence of another significant promotor polymorphism at -550 H/L which can influence the secreting serum MBL level. Furthermore, some researchers have reported an association between certain MBL promotor genotype and increased incidence of clinical manifestations [34] [35] [36] [37] [38] . We have investigated the possible association of MBL2-221X/ Y promotor genotype with the broader spectrum of the SLE patient's gender, age at disease onset and clinical manifestations. No association was found with the patients' gender which may be due to the limited number of male participants. Furthermore, no association was found with the age at disease onset which was in agreement with a Chinese study [39] even though they included 150 juvenile onset SLE patients. In disagreement to our work, a study from Denmark reported a significant association between XY genotype and early onset SLE [34]. This difference can be explained by using different genotyping techniques as they used PCR-sequence specific priming rather than the PCR-RFLP used in this study. In our study we detected a significant association between XY genotype and weight loss, discoid rash and alopecia. In accordance to these findings, another study [40] comparing MBL promotor genotype effect between SLE and dermatomyositis patients detected a significant association between XY genotype and cutaneous symptoms only in SLE patients. On the other hand, our results disagree with that of an earlier Danish study on 315 patients [34] and this difference could be due to the variation between populations in SLE symptoms or in the number of participants. In the present study there was a significant association between XY genotype and APL syndrome which confirmed the findings on a Caucasian [41] and Brazilian [42] population. The significant association between vasculitis and XY genotype in the current study verified the findings of a previous study [41] . A significant association between XY genotype and the neurological symptoms was detected. However, in Southern Brazil they could not detect any association [40] . This difference could be explained by the difference in ethnic populations. Although we had a high frequency of lupus nephritis (LN) we did not detect any association with MBL genotype. Our result was in agreement with studies on different ethnic groups [15, 34, 39, 40] . However, in another study from Tanta on Egyptian SLE patients, MBL2 mutant genotypes AO + OO were significantly higher in SLE patients compared to control and were more likely to produce anti-ds DNA and be associated with LN [42] . Significant association with renal failure has been reported [41] . However, we could not support this finding because none of our patients had renal failure.
In this study, we did not detect any association between cardiac manifestations and MBL genotype. Our result confirms a previous study on Chinese children [39] and is in disconformity with those of a study on Caucasians [41] with a comparable number of participants. They detected a significant 3.3 times higher association between cardiac affection and XY genotype. This could be explained by the different genotyping method used. In another Egyptian study on SLE patients, MBL A/B and B/B were significantly higher (47%) than in the control (29%) and were significantly associated with increased intima-media thickness, dyslipidemia, increased disease activity and hypocomplementemia suggesting its role as a risk factor for atherosclerosis [43] . No association was found between MBL2 genotype and pulmonary or GIT symptoms which is in accordance to the findings of another study on Chinese children [39] . There was no association between MBL2 genotype and autoimmune hemolytic anemia which is consistent with that of other studies carried out on different ethnicities [39, 40, 44] .
In the current study the YY genotype was significantly associated only with the low serum complement level. On the contrary, another study [41] recorded an association between hypocomplementemia and the XY genotype. However this could be explained by different degrees of activity between both studies. In our study, XY genotype had only a significant association with positive serum ACL antibodies. Our finding is in harmony with those of reports from Caucasian [41] and Brazilian [44] populations.
In this study, SLEDAI did not correlate with MBL2 promotor genotype. This agrees with the results of other studies [15, 34, 39] . But in a long term follow up study, there was a significant correlation between SLEDAI and XY genotype [45] . Additionally, in this study, SLICC/ACR DI did not correlate with MBL2 promotor genotype. A significant correlation between SLICC/ACR DI and XY genotype was only detected once [41] in a study including 11 patients with renal failure which was absent in the present study.
In conclusion, our study pinpoints MBL2 -221X/Y gene promotor polymorphisms as possible key-players in SLE development. Moreover, it also seems to be associated with some clinical and laboratory manifestations of SLE. Further studies are needed to clarify the role of MBL2 promotor gene polymorphism and other SNPs in SLE with long term follow up. A regression test would be of value to detect the role of MBL as a risk factor for SLE activity and manifestations. Another study is needed to compare serum MBL level among significant SNPs and follow up its level during SLE remission and exacerbation.
